Back to Search
Start Over
A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B
- Source :
- Medicine. 98:e16778
- Publication Year :
- 2019
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2019.
-
Abstract
- Background:Tenofovir disoproxil fumarate (TDF) has been widely recommended as a first-line antiviral agent to treat chronic hepatitis B (CHB). Qingzhong and Viread, formulations of TDF commercialized by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd and GlaxoSmithKline, respectively, have b
- Subjects :
- medicine.medical_specialty
Drug compounding
Tenofovir
business.industry
Treatment outcome
General Medicine
Hepatitis B
medicine.disease
Gastroenterology
law.invention
Double blind
03 medical and health sciences
0302 clinical medicine
Multicenter study
Chronic hepatitis
Randomized controlled trial
law
030220 oncology & carcinogenesis
Internal medicine
Medicine
030212 general & internal medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 15365964 and 00257974
- Volume :
- 98
- Database :
- OpenAIRE
- Journal :
- Medicine
- Accession number :
- edsair.doi...........7e549c4b85e9371b1ddcc471c2571371